uniQure (NASDAQ:QURE) Stock Price Up 6.5% – Here’s Why

uniQure N.V. (NASDAQ:QURE) shares rose 6.5% on Monday . The stock traded as high as $24.66 and last traded at $24.96. Approximately 1,082,899 shares traded hands during mid-day trading, a decline of 43% from the average daily volume of 1,904,691 shares. The stock had previously closed at $23.43.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Wells Fargo & Company lowered their price objective on uniQure from $80.00 to $60.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 12th. Chardan Capital restated a “buy” rating and issued a $53.00 price target on shares of uniQure in a research note on Thursday, December 4th. Stifel Nicolaus lowered their price target on shares of uniQure from $50.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday, December 11th. The Goldman Sachs Group dropped their price objective on shares of uniQure from $56.00 to $38.00 and set a “neutral” rating for the company in a research note on Tuesday, November 4th. Finally, HC Wainwright restated a “buy” rating and set a $70.00 target price on shares of uniQure in a research report on Tuesday, February 10th. Ten equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $58.33.

uniQure Price Performance

The business has a 50-day moving average of $23.60 and a two-hundred day moving average of $29.55. The company has a current ratio of 7.12, a quick ratio of 7.12 and a debt-to-equity ratio of 0.23. The firm has a market cap of $1.52 billion, a P/E ratio of -5.57 and a beta of 0.66.

Insider Activity

In other news, Director Jack Kaye sold 6,390 shares of the company’s stock in a transaction that occurred on Friday, January 9th. The stock was sold at an average price of $27.28, for a total value of $174,319.20. Following the completion of the transaction, the director owned 20,439 shares of the company’s stock, valued at $557,575.92. This represents a 23.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Robert Gut sold 25,613 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $24.62, for a total transaction of $630,592.06. Following the sale, the director directly owned 32,342 shares in the company, valued at $796,260.04. The trade was a 44.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 4.79% of the company’s stock.

Institutional Trading of uniQure

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Private Trust Co. NA bought a new stake in shares of uniQure in the 3rd quarter valued at about $28,000. Jones Financial Companies Lllp raised its position in shares of uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 509 shares during the last quarter. CIBC Private Wealth Group LLC acquired a new position in shares of uniQure in the third quarter worth approximately $50,000. Torren Management LLC bought a new stake in uniQure in the fourth quarter valued at approximately $28,000. Finally, FNY Investment Advisers LLC boosted its holdings in uniQure by 76.7% in the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 718 shares during the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.